The combination of tiragolumab and atezolizumab did not improve progression-free survival in patients with stage III non-small-cell lung cancer after chemoradiation
fondazionebonadonna.org/en/tiragolum...
#FondazioneBonadonna #Oncology #CancerResearch
@mauriziocallari.bsky.social

Adding belzutifan to adjuvant pembrolizumab improves disease-free survival but increases adverse events in resected clear-cell renal cell carcinoma at increased risk for recurrence
fondazionebonadonna.org/en/pembroliz...
#FondazioneBonadonna #Oncology #CancerResearch

Results from BREAKWATER Cohort 3 trial show clinically meaningful improvements in objective response rate and progression-free survival for encorafenib, cetuximab plus FOLFIRI in BRAF V600E-mutant colorectal cancer
fondazionebonadonna.org/en/encorafen...
#FondazioneBonadonna #CancerResearch

The oral RAS(ON) multiselective inhibitor daraxonrasib shows a significantly longer overall survival and progression-free survival in patients with previously treated metastatic pancreatic ductal adenocarcinoma
www.fondazionebonadonna.eu/en/daraxonra...
#FondazioneBonadonna #Oncology #CancerResearch

ROSELLA trial shows a benefit in overall survival with relacorilant added to nab-paclitaxel in patients with platinum-resistant ovarian cancer
www.fondazionebonadonna.eu/en/relacoril...
#FondazioneBonadonna #Oncology #CancerResearch